EVIDERA, INC.
BETHESDA, MD

Evidera, Inc., a subsidiary of Pharmaceutical Product Development, LLC (PPD), serves as the leading provider of evidence-based solutions to assess and demonstrate real-world effectiveness, safety, and value for biopharmaceutical and biotechnology products. Established in 2013 and integrated into PPD in 2016, Evidera operates within a global contract research organization framework with a focus on optimizing market access and commercial potential from early development stages through the loss of exclusivity. Headquartered in Bethesda, Florida, but with operational roots extending to Waltham, Massachusetts, Evidera has expanded its influence across 38 countries. The company's approach involves robust scientific expertise combined with global operational capabilities to aid biopharma companies in value demonstration initiatives. Evidera employs a diverse workforce equipped with proactive mindsets and extensive industry experience ranging from veteran leaders to emerging talents. This team diversity facilitates innovative ways of engaging patient advocacy groups and enhancing study design through increased patient outreach. Notable is Evidera's role in influencing health economic decisions, such as their contribution to the National Institute for Health and Care Excellence (NICE) in adjusting reimbursement strategies for metastatic castration-resistant prostate cancer (mCRPC) treatments across conservative healthcare systems. Their global endeavors have also supported urgent patient treatment programs within tight timeframes. Offices are accessible via multiple contact numbers for inquiries and further collaboration details. Evidera’s leadership team includes Kelly McGinnis as Director, with Henry Geroek and James Bruni serving as Assistants. The company's incorporation in Florida was registered under the file number F16000003503, indicating a well-established entity since its inception on August 5, 2016.